Bandaram Pharma

Which are the latest news on Bandaram Pharma?

Why is Bandaram Pharma Packtech Ltd falling/rising?

As of 05-Sep, Bandaram Pharma Packtech Ltd's stock price is rising to Rs 21.70, up 4.58%, driven by a strong weekly gain of 20.56% and increased investor participation. Despite a year-to-date decline of 27.11%, today's trading shows positive momentum with significant intraday gains.

As of 05-Sep, Bandaram Pharma Packtech Ltd's stock price is rising, currently at Rs 21.70, reflecting an increase of Rs 0.95 or 4.58%. This upward movement is supported by a strong performance over the past week, where the stock has gained 20.56%, significantly outperforming the Sensex, which has declined by 0.97% during the same period. Additionally, the stock has shown a notable intraday high of Rs 23.5, representing a 13.25% increase at its peak today.<BR><BR>The stock's performance today has also outperformed its sector by 9.47%. Furthermore, there has been a rise in investor participation, with delivery volume increasing by 2.5% compared to the 5-day average. Despite the stock's year-to-date decline of 27.11% and a one-year drop of 37.10%, the current trading activity indicates a positive shift, with high volatility observed today at 6.67%. <BR><BR>Overall, the combination of strong recent performance, increased investor interest, and significant intraday gains contributes to the rising stock price of Bandaram Pharma Packtech Ltd.

Who are in the management team of Bandaram Pharma?

The management team of Bandaram Pharma includes Kishan Prasad Palayu (Chairman), Mahesh Kumar Vellaboyina, Sangam Venkateshwar Rao (both Non Executive Directors), Namrata Chadha (Non Executive Independent Director), and Shivarama Babu Velchuri (Executive Director).

The management team of Bandaram Pharma includes the following individuals:<BR><BR>1. Kishan Prasad Palayu - Chairman<BR>2. Mahesh Kumar Vellaboyina - Non Executive Director<BR>3. Sangam Venkateshwar Rao - Non Executive Director<BR>4. Namrata Chadha - Non Executive Independent Director<BR>5. Shivarama Babu Velchuri - Executive Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Bandaram Pharma do?

Bandaram Pharma Packtech Ltd operates in the healthcare services sector, focusing on recycled paper processing. It was incorporated in 1991 and reported net sales of 24 Cr and a net profit of 1 Cr for June 2026, with a market cap of INR 33 Cr.

Overview: <BR>Bandaram Pharma Packtech Ltd operates in the healthcare services industry, focusing on the processing and supply of recycled paper, and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated on December 2, 1991, initially to manufacture latex gloves. It later ventured into the paper industry in 2022, discontinuing its computer sales and AMC business. The latest reported quarterly results are for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 24 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 33 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 0.07% <BR>Debt-Equity: 0.87 <BR>Return on Equity: 1.23% <BR>Price to Book: 1.24 <BR><BR>Contact Details: <BR>Address: 601 5th Floor Oxford Towers, Old Airport Road Kodihalli Bangalore Karnataka : 560008 <BR>Email: contact@shivamedicare.com <BR>Website: http://www.bandaram.com

Who are the peers of the Bandaram Pharma?

Bandaram Pharma's peers include Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, Centenial Surgic, Deccan Healthcar, GKB Ophthalmics, Tejnaksh Health., and Chennai Meena. Bandaram Pharma has below-average management risk and a 1-year return of -41.87%, lower than its peers.

Peers: The peers of Bandaram Pharma are Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, Centenial Surgic, Deccan Healthcar, GKB Ophthalmics, Tejnaksh Health., and Chennai Meena.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shree Pacetronix, Amkay Products, N G Industries, and Sunrest Lifescie, while Average management risk is found at KMS Medisurgi. Below Average management risk is noted for Centenial Surgic, Deccan Healthcar, GKB Ophthalmics, Bandaram Pharma, Tejnaksh Health., and Chennai Meena. Growth is Excellent at Bandaram Pharma and Good at Shree Pacetronix, Deccan Healthcar, and GKB Ophthalmics, while Below Average growth is seen at Amkay Products, KMS Medisurgi, N G Industries, Centenial Surgic, Tejnaksh Health., and the rest. Capital Structure is Good for Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, Deccan Healthcar, GKB Ophthalmics, and Tejnaksh Health., while Average is noted for Centenial Surgic, and Below Average for Bandaram Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Amkay Products at 28.50%, while the lowest is Deccan Healthcar at -33.81%. Bandaram Pharma's 1-year return of -41.87% is lower than both. Additionally, the peers with negative six-month returns include Deccan Healthcar, N G Industries, and Bandaram Pharma.

How big is Bandaram Pharma?

As of 31st August, Bandaram Pharma Packtech Ltd has a market capitalization of 33.00 Cr, with recent net sales of 78.77 Cr and a net profit of 0.99 Cr.

As of 31st August, Bandaram Pharma Packtech Ltd has a market capitalization of 33.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 78.77 Cr and a Net Profit of 0.99 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 12.65 Cr and Total Assets of 38.92 Cr.

Should I buy, sell or hold Bandaram Pharma Packtech Ltd?

When is the next results date for Bandaram Pharma Packtech Ltd?

The next results date for Bandaram Pharma Packtech Ltd is 13 August 2026.

The next results date for Bandaram Pharma Packtech Ltd is scheduled for 13 August 2026.

Are Bandaram Pharma Packtech Ltd latest results good or bad?

Bandaram Pharma Packtech Ltd's latest results show strong revenue growth of 76.95% quarter-on-quarter and 209.31% year-on-year, but profitability has declined significantly, with net profit down 52.63% from the previous quarter. Overall, the financial metrics indicate more concerns than positives, suggesting caution for investors.

Bandaram Pharma Packtech Ltd's latest results present a mixed picture, leaning towards negative overall. In Q4 FY26, the company reported a significant revenue increase of 76.95% quarter-on-quarter and an impressive 209.31% year-on-year growth, reaching ₹26.26 crores. However, this strong top-line performance was overshadowed by a substantial decline in profitability. <BR><BR>The net profit fell to ₹0.09 crores, reflecting a 52.63% decrease from the previous quarter and a 40% drop year-on-year. Operating margins also deteriorated sharply, dropping to 3.12% from 6.81% in the prior quarter, indicating severe cost pressures and challenges in maintaining profitability despite higher sales.<BR><BR>The company's financial health is further questioned by low return ratios, with a return on equity (ROE) of just 5.15% and a return on capital employed (ROCE) of 5.75%. Additionally, the high debt levels and negative operating cash flow raise concerns about its financial stability.<BR><BR>Overall, while Bandaram Pharma has demonstrated strong revenue growth, the significant decline in profitability and operational challenges suggest that the latest results are more concerning than positive. Investors should be cautious given the current financial metrics and market positioning.

How has been the historical performance of Bandaram Pharma?

Bandaram Pharma has shown steady growth in net sales and profit over the past three years, with net sales increasing from 18.73 Cr in Mar'23 to 36.96 Cr in Mar'25, and profit after tax rising from 0.26 Cr to 0.99 Cr. Total assets and liabilities also grew significantly during this period, while cash flow from operating activities remained negative but stable.

Answer:<BR>The historical performance of Bandaram Pharma shows a steady growth in net sales and profit over the past three years.<BR><BR>Breakdown:<BR>Bandaram Pharma's net sales increased from 18.73 Cr in Mar'23 to 34.08 Cr in Mar'24, and further to 36.96 Cr in Mar'25, indicating a consistent upward trend. Total operating income mirrored this growth, reaching 36.96 Cr in Mar'25. The total expenditure also rose, from 17.57 Cr in Mar'23 to 34.14 Cr in Mar'25, primarily driven by raw material costs and employee expenses. Operating profit (PBDIT) improved from 1.35 Cr in Mar'23 to 2.91 Cr in Mar'25, while profit before tax rose from 0.33 Cr to 1.32 Cr in the same period. Profit after tax followed suit, increasing from 0.26 Cr in Mar'23 to 0.99 Cr in Mar'25. The company's total assets grew significantly from 20.17 Cr in Mar'23 to 38.92 Cr in Mar'25, alongside total liabilities which increased from 20.17 Cr to 38.92 Cr. Cash flow from operating activities remained negative but stable at -4.00 Cr in both Mar'24 and Mar'25, while cash flow from financing activities showed a positive trend, reaching 5.00 Cr in Mar'25. Overall, Bandaram Pharma has demonstrated solid growth in sales and profitability, alongside an increase in both assets and liabilities.

Is Bandaram Pharma overvalued or undervalued?

As of November 28, 2025, Bandaram Pharma is considered overvalued with a PE ratio of 216.00 and a valuation grade of attractive, despite strong short-term returns, due to negative year-to-date and one-year performance.

As of 28 November 2025, Bandaram Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its worth. The company is currently considered overvalued, with a PE ratio of 216.00, a Price to Book Value of 3.71, and an EV to EBITDA of 30.28. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Bandaram Pharma's PE ratio is significantly higher than Lenskart Solutions at 241.34 and Poly Medicure at 54.51, both of which are also considered expensive. The PEG ratio of 51.30 further emphasizes the overvaluation, especially when compared to the industry standards. While Bandaram Pharma has shown strong short-term returns, outperforming the Sensex in the past week and month, its year-to-date and one-year returns are negative, which adds to the concern regarding its current valuation.

Who are the top shareholders of the Bandaram Pharma?

The top shareholder of Bandaram Pharma is B. Deepak Reddy, holding 39.38% of the shares, with no pledged promoter holdings. The highest public shareholder is Sanivarapu Jhansi at 6.54%, while individual investors collectively own 23.74%.

The top shareholders of Bandaram Pharma include the promoters, with B. Deepak Reddy holding the largest stake at 39.38%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sanivarapu Jhansi, who owns 6.54% of the shares. Additionally, individual investors collectively hold 23.74% of the company's shares.

What is the technical trend for Bandaram Pharma?

As of May 5, 2025, Bandaram Pharma's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish signals from the MACD, Bollinger Bands, and moving averages, alongside a bearish monthly RSI.

As of 5 May 2025, the technical trend for Bandaram Pharma has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both signaling bearish trends, alongside a bearish reading from the daily moving averages. The monthly RSI also indicates bearish momentum, while the KST and Dow Theory show mildly bearish conditions on a monthly basis. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market for Bandaram Pharma.

Has Bandaram Pharma declared dividend?

Bandaram Pharma Packtech Ltd has declared a 1% dividend, amounting to 0.1 per share, with an ex-date of September 20, 2024. Total returns have varied significantly across periods, with a 5-year total return of 166.14%, despite some shorter periods showing negative returns.

Bandaram Pharma Packtech Ltd has declared a 1% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1%<BR>- Amount per share: 0.1<BR>- Ex-date: 20 Sep 2024<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -15.87%, with a dividend return of 0%, resulting in a total return of -15.87%.<BR><BR>Over the 1-year period, the price return was 7.69%, the dividend return was 0.30%, leading to a total return of 7.99%.<BR><BR>For the 2-year period, the price return was -49.75%, with no dividend return, resulting in a total return of -49.75%.<BR><BR>In the 3-year period, the price return was 0%, and there was no dividend return, leading to a total return of 0.0%.<BR><BR>During the 4-year period, the price return was 165.45%, with no dividend return, resulting in a total return of 165.45%.<BR><BR>For the 5-year period, the price return was 165.45%, with a dividend return of 0.69%, leading to a total return of 166.14%.<BR><BR>Overall, while Bandaram Pharma has declared a dividend, the total returns over various periods show significant variability, with some periods reflecting substantial gains, particularly over the longer term, despite certain periods showing negative returns.